The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss pharmaceutical giant Novartis (NYSE: NVS) and China-based Alibaba Health Information Technology Ltd (HKG: 0241). The collaboration aims to utilize digitization to enhance patient medication accessibility and provide one-stop health management services. Financial details of the partnership were not disclosed.
Partnership Overview
Novartis will contribute its expertise and advanced treatment plans to establish an online disease special zone with Alibaba Health. Alibaba Health will leverage its strengths in e-commerce, logistics, big data, and Internet healthcare to support the initiative. This joint effort is expected to significantly improve patient outcomes through enhanced accessibility and integrated health management services.
Focus on Cardiovascular Disease
In the cardiovascular disease area, Novartis brings its innovative therapy Entresto (valsartan + sacubitril), which is used for heart failure and hypertension management. Patients with hypertension can access blood pressure management knowledge through the “Alibaba Health Specialist Center” and live-streaming sessions. Additionally, the partnership has established a hypertension patient community to improve medication compliance and overall patient engagement.-Fineline Info & Tech
